Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. [electronic resource]
Producer: 20120509Description: 473-481.e4 p. digitalISSN:- 1528-0012
- Adult
- Anti-Infective Agents -- administration & dosage
- Chemistry, Pharmaceutical
- Chi-Square Distribution
- Crohn Disease -- diagnosis
- Delayed-Action Preparations
- Double-Blind Method
- Europe
- Female
- Gastrointestinal Agents -- administration & dosage
- Humans
- Israel
- Logistic Models
- Male
- Middle Aged
- Odds Ratio
- Remission Induction
- Rifamycins -- administration & dosage
- Rifaximin
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Video-Audio Media
There are no comments on this title.
Log in to your account to post a comment.